drug
EPKINLY
updated 6mo agoby Genmab US Inc
community read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
News(10)
- Genmab soars to record highs after cancer drug succeeds in key trialThe drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become a new treatment standard for a form of head and neck cancer.biopharma_dive · 18d ago
- Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readoutAnalysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.biospace · 19d ago
- Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readoutAnalysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.biospace · 19d ago
- Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trialExtending both progression-free and overall survival, Genmab’s Rina-S “sets a high bar for future competition” in a market served by AbbVie, analysts said.biospace · 21d ago
- Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosionBracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.biospace · 27d ago
- Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, moreNew data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this…biospace · 1mo ago
- Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trialThe better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.biopharma_dive · 1mo ago
- AbbVie, Genmab's Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse la…biospace · 1mo ago
- AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to PolivyAbbVie and Genmab said their T-cell engager Epkinly passed a late-stage trial in first-line diffuse large B-cell lymphoma, clearing the way for a potential market showdown with Roche’s antibody-dru…endpoints · 1mo ago
- AbbVie and Genmab's latest win brings Epkinly closer to label expansionAbbVie and Genmab’s bispecific antibody Epkinly succeeded in combination with a widely used cancer drug, bringing it one step closer to a potential label expansion in diffuse large B cell lymphoma.…endpoints · 4mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that